The expression levels of MLKL were analyzed by immunohistochemistry in 613 patients with various cancers, including breast cancer, gastric cancer, cervical squamous cell carcinoma, ovarian cancer, colon cancer, and pancreatic adenocarcinoma; differences in the expression levels of MLKL were observed in patients with the same type of cancer, and low levels of MLKL expression were strongly associated with the advanced tumor stage and metastasis to the lymph nodes [93]. Here, MLKL is linked to malignant colon neoplasm.